Table 1.

Demographics and baseline characteristics

CharacteristicsAll patients (N = 36)
Age, median (range), y68 (26-86)
Sex, n (%)
 Male23 (64)
 Female13 (36)
Race/ethnicity, n (%)
 White30 (83)
 African American4 (11)
 Asian1 (3)
 Hispanic1 (3)
Evaluable aspirates for TP53 mutation status, n (%)16 (44)
 Negative13 (36)
 Positive3 (8)
Evaluable aspirates for FLT3 mutation status, n (%)23 (64)
 Negative20 (56)
 FLT3 ITD1 (3)
 FLT3 TKD mutation1 (3)
 FLT3 ITD and TKD mutation1 (3)
ECOG performance status, n (%)
 010 (28)
 121 (58)
 25 (14)
Prior stem cell transplant, n (%)4 (11)
Prior lines of therapy, n (%)35 (97)
 110 (28)
 210 (28)
 ≥315 (42)
Prior treatment with hypomethylating agents, n (%)
 Azacitidine15 (42)
 Decitabine13 (36)
Prior treatment with 7+3, n (%)
 Cytarabine plus daunorubicin9 (25)
 Cytarabine plus idarubicin7 (19)
 Cytarabine plus epirubicin1 (3)
 Not specified1 (3)
  • ECOG, Eastern Cooperative Oncology Group; ITD, internal tandem duplication; TKD, tyrosine kinase domain.